- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
For: Thromboembolic diseaseBulgaria · Poland · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Master Protocol for a Phase 2 Randomized, Double-blind, Placebo-controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies against Factor XI for Prevention of Venous Thromboembolism in Patients with a Peripherally Inserted Central Catheter (ROXI-CATH).
This study is testing new medicines to help prevent blood clots in people who have a long-term drip called a PICC line. We want to see if these medicines are safe and if they can stop clots from forming. It's a key step in finding better ways to protect patients.
For: Venous ThromboembolismSpain · Romania · Bulgaria